These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 7480380)

  • 21. Management of hostile, suspicious patients. Trifluoperazine versus haloperidol.
    O'Brien CP; DiGiacomo JN; Webb W
    Dis Nerv Syst; 1974 Feb; 35(2):75-8. PubMed ID: 17894044
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol.
    Keefe RS; Seidman LJ; Christensen BK; Hamer RM; Sharma T; Sitskoorn MM; Lewine RR; Yurgelun-Todd DA; Gur RC; Tohen M; Tollefson GD; Sanger TM; Lieberman JA
    Am J Psychiatry; 2004 Jun; 161(6):985-95. PubMed ID: 15169686
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Drug-induced dystonia.
    Swett C
    Am J Psychiatry; 1975 May; 132(5):532-4. PubMed ID: 1119613
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risperidone and olanzapine versus another first generation antipsychotic in patients with schizophrenia inadequately responsive to first generation antipsychotics.
    Chen JJ; Chan HY; Chen CH; Gau SS; Hwu HG
    Pharmacopsychiatry; 2012 Mar; 45(2):64-71. PubMed ID: 22086749
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A probable neuroleptic effect on platelet monoamine oxidase in chronic schizophrenic patients.
    DeLisi LE; Wise CD; Bridge TP; Rosenblatt JE; Wagner RL; Morihisa J; Karson C; Potkin SG; Wyatt RJ
    Psychiatry Res; 1981 Feb; 4(1):95-107. PubMed ID: 6111821
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Schizophrenia and the stroop effect.
    Henik A; Salo R
    Behav Cogn Neurosci Rev; 2004 Mar; 3(1):42-59. PubMed ID: 15191641
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Neuroleptics and cognition].
    Brunnauer A; Geiger E; Laux G
    Psychiatr Prax; 2003 May; 30 Suppl 2():S106-9. PubMed ID: 14509053
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Response to antipsychotic medication: the doctor's and the consumer's view.
    Van Putten T; May PR; Marder SR
    Am J Psychiatry; 1984 Jan; 141(1):16-9. PubMed ID: 6691455
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Long-term therapy of chronic schizophrenic patients with haloperidol decanoate].
    Roncoroni D
    Psychiatr Prax; 1984 Mar; 11(2):56-8. PubMed ID: 6144121
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Effects of thiothixene on schizophrenic symptoms in a long-term therapeutic scheme. Comparative study with butyrophenone derivative].
    Vianna Filho U; Muniz AF; Terra SO; Bueno JR
    J Bras Psiquiatr; 1971; 20(3):193-204. PubMed ID: 5164436
    [No Abstract]   [Full Text] [Related]  

  • 31. Dyscognitive syndromes in neuroleptic therapy.
    Strauss WH; Klieser E; Luethcke H
    Pharmacopsychiatry; 1988 Nov; 21(6):298-9. PubMed ID: 2907630
    [No Abstract]   [Full Text] [Related]  

  • 32. Effects of antipsychotic treatment on polysomnographic measures in schizophrenia: a replication and extension.
    Maixner S; Tandon R; Eiser A; Taylor S; DeQuardo JR; Shipley J
    Am J Psychiatry; 1998 Nov; 155(11):1600-2. PubMed ID: 9812125
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Stability of set-shifting and planning abilities in patients with schizophrenia.
    Tyson PJ; Laws KR; Roberts KH; Mortimer AM
    Psychiatry Res; 2004 Dec; 129(3):229-39. PubMed ID: 15661316
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Importance of pharmacologic control in PET studies: effects of thiothixene and haloperidol on cerebral glucose utilization in chronic schizophrenia.
    Bartlett EJ; Wolkin A; Brodie JD; Laska EM; Wolf AP; Sanfilipo M
    Psychiatry Res; 1991 Oct; 40(2):115-24. PubMed ID: 1763142
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Haloperidol and thiothixene in the long-term treatment of chronic schizophrenic outpatients in an urban community: social and vocational adjustment.
    Engelhardt DM; Rudorfer L; Rosen B
    J Clin Psychiatry; 1978 Dec; 39(12):834-40. PubMed ID: 721787
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia.
    Purdon SE; Jones BD; Stip E; Labelle A; Addington D; David SR; Breier A; Tollefson GD
    Arch Gen Psychiatry; 2000 Mar; 57(3):249-58. PubMed ID: 10711911
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent.
    Heel RC; Brogden RN; Speight TM; Avery GS
    Drugs; 1978 Mar; 15(3):198-217. PubMed ID: 25167
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High and low dose thiothixene treatment in chronic schizophrenia.
    Gardos G; Orzack MH; Finn G; Cole JO
    Dis Nerv Syst; 1974 Feb; 35(2):53-8. PubMed ID: 17894041
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of haloperidol and risperidone on psychomotor performance relevant to driving ability in schizophrenic patients compared to healthy controls.
    Soyka M; Winter C; Kagerer S; Brunnauer M; Laux G; Möller HJ
    J Psychiatr Res; 2005 Jan; 39(1):101-8. PubMed ID: 15504428
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Urinary incontinence in patients receiving neuroleptics.
    Nurnberg HG; Ambrosini PJ
    J Clin Psychiatry; 1979 Jun; 40(6):271-4. PubMed ID: 36372
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.